Maze Therapeutics, Inc. Common Stock (MAZE) - Total Liabilities
Based on the latest financial reports, Maze Therapeutics, Inc. Common Stock (MAZE) has total liabilities worth $78.01 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Maze Therapeutics, Inc. Common Stock net asset momentum to track the company's year-over-year net asset growth rate.
Maze Therapeutics, Inc. Common Stock - Total Liabilities Trend (2022–2025)
This chart illustrates how Maze Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Maze Therapeutics, Inc. Common Stock to measure how efficiently the company converts operating cash flow to free cash.
Maze Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Maze Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Serena Energia S.A.
SA:SRNA3
|
Brazil | R$15.23 Billion |
|
Privi Speciality Chemicals Limited
NSE:PRIVISCL
|
India | Rs17.29 Billion |
|
SPG Co. Ltd
KQ:058610
|
Korea | ₩170.49 Billion |
|
Harbin Electric
F:HP6H
|
Germany | €63.59 Billion |
|
Xiamen Solex High-Tech Industries Co Ltd
SHG:603992
|
China | CN¥1.12 Billion |
|
Changbai Mountain Tourism Co Ltd
SHG:603099
|
China | CN¥289.34 Million |
|
Shanghai Pret Composites
SHE:002324
|
China | CN¥8.21 Billion |
|
Silicon2 Co. Ltd.
KQ:257720
|
Korea | ₩249.59 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Maze Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Maze Therapeutics, Inc. Common Stock worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Maze Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Maze Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of Maze Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $42.16 Million | -3.38% |
| 2024-12-31 | $43.64 Million | -28.99% |
| 2023-12-31 | $61.45 Million | +26.66% |
| 2022-12-31 | $48.51 Million | -- |
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral s… Read more